Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Neoplasms 4Neoplasm Metastasis 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Leukemia, Myeloid, Acute 2Colorectal Neoplasms 2Central Nervous System Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Solid Tumor 1Small Cell Lung Carcinoma 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Myelodysplastic Syndromes 1Microphthalmia, Isolated, with Coloboma 5 1Medulloblastoma 1Leukemia, Myelomonocytic, Chronic 1Hereditary Breast and Ovarian Cancer Syndrome 1Head and Neck Neoplasms 1Fanconi Anemia 1Endometrial Neoplasms 1Desmoplastic Small Round Cell Tumor 1Carcinoma, Squamous Cell 1Brain Neoplasms 1Anus Neoplasms 1Advanced Cancer 1

Interventions

fludarabine phosphate 7Cyclophosphamide 6Antilymphocyte Serum 6Busulfan 5fludarabine 4Melphalan 4Radiotherapy 3Peripheral Blood Stem Cell Transplantation 3Methylprednisolone 3Filgrastim 3Cord Blood Stem Cell Transplantation 3thymoglobulin 2SRA737 2Mycophenolic Acid 2Granulocyte Colony-Stimulating Factor 2AP 1903 reagent 2sargramostim 1prexasertib 1Whole-Body Irradiation 1Thiotepa 1Tacrolimus 1Stem Cell Transplantation 1Spectrometry, Fluorescence 1Reverse Transcriptase Polymerase Chain Reaction 1Quercetin 1Polymerase Chain Reaction 1Optical Imaging 1Molecular Diagnostic Techniques 1Microarray Analysis 1Immunoenzyme Techniques 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fanconi Anemia × prexasertib × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡